Project Grant R01HL179813
Award Date
5/1/25
Completion Date
2/28/29
Dollars Obligated
$700K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $727,059 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to the University of California, Los Angeles (UCLA) to support research on nonvesicular cholesterol transport mechanisms. The 4-year project, spanning August 2024 to May 2028, aims to identify new factors involved in the nonvesicular transport of cholesterol from the plasma membrane to the endoplasmic reticulum, and to define the physiological...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $773,259 to the University of California, Los Angeles (UCLA) to fund research on the role of membrane cholesterol in regulating vascular inflammation. The key objectives of this 4-year project are to: 1) identify novel cholesterol-responsive proteins in the vasculature using chemical biology approaches; 2) elucidate the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $787,267 to Yale University to conduct research on the role of cholesterol biosynthetic intermediates and derivatives in modulating the immune response of macrophages in atherosclerosis. The award aims to determine whether genetic deletion of the DHCR24 enzyme in macrophages can attenuate atherosclerosis progression, and whether...
This Project Grant award of $506,984 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the role of the endocytic trafficking protein LRP1 in the cardiac neural crest cell lineage and its impact on congenital heart defects. The University of Pittsburgh, the prime awardee, will conduct a combination of in vivo and in vitro experiments using genetically modified mouse models to: Examine...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $457,513 to the University of Texas at Arlington (UTA) to investigate the role of the enzyme indoleamine-2,3-dioxygenase 1 (IDO1) and its downstream metabolite kynurenine in regulating cholesterol homeostasis and macrophage function under inflammatory conditions. The 3-year project aims to elucidate the signaling mechanisms...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Program (CFDA 93.837), provides $784,046 to the Rector & Visitors of the University of Virginia (UVA) to conduct research modeling cell-specific signaling pathways involving the LRP1 receptor in the context of acute myocardial infarction (AMI) and heart failure. The award aims to 1) expand and validate a signaling network that predicts how early...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $874,792 to Vanderbilt University Medical Center from July 2024 to June 2028. The project aims to address residual atherosclerotic cardiovascular disease (ASCVD) risk among patients who continue to experience myocardial infarctions or strokes despite treatment to lower LDL-cholesterol and blood pressure. The key objectives are to: (1)...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,229,404 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Yale University to investigate the role of novel lysoplasmalogenase enzymes in regulating macrophage immunometabolic responses in cardiovascular disease. The project aims to elucidate how the LXR/miR-33/TMEM86A signaling pathway contributes to chronic vascular inflammation in atherosclerotic lesions. Yale will utilize cutting-edge genomic and metabolomic...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), funds research into RBPMS, a novel RNA splicing regulator of cardiac function and disease. The $100,480 award, effective July 15, 2024, supports a study conducted by the University of Texas Southwestern Medical Center to characterize how RBPMS regulates cardiomyocyte contraction through alternative RNA splicing, and explore the...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), will provide $381,250 to Clemson University to conduct research on identifying novel atheroprotective mechanisms related to vascular smooth muscle cell cholesterol efflux. The research aims to rigorously analyze the potential atheroprotective impacts of increased expression of the ABC transporters ABCA1 and ABCG1 in...